Skip to main content
Clinical Trials/NCT00510406
NCT00510406
Completed
Phase 2

A Randomized, Double-blind, Parallel Group, Placebo Controlled, Multi Center Dose Ranging Study of Solifenacin Succinate in Combination With Tamsulosin Hydrochloride Compared With Solifenacin Succinate Monotherapy and Tamsulosin Hydrochloride Monotherapy in Males With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

Astellas Pharma Inc0 sites919 target enrollmentJanuary 2007

Overview

Phase
Phase 2
Intervention
tamsulosin hydrochloride
Conditions
Lower Urinary Tract Symptoms
Sponsor
Astellas Pharma Inc
Enrollment
919
Primary Endpoint
Assess whether the combination of solifenacin succinate and tamsulosin hydrochloride provides improved efficacy compared to tamsulosin hydrochloride alone in males with LUTS associated with BPH
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The study will examine the efficacy,safety and tolerability of combination therapy of tamsulosin and solifenacin compared to placebo and monotherapy of tamsulosin and solifenacin in the treatment of males with LUTS associated with BPH.

Detailed Description

Placebo Solifenacin succinate Tamsulosin hydrochloride Tamsulosin hydrochloride + solifenacin succinate The primary comparison will be the combination treatment with tamsulosin hydrochloride monotherapy. Other comparisons will be: Placebo and combination treatment. Solifenacin monotherapy and combination treatment

Registry
clinicaltrials.gov
Start Date
January 2007
End Date
September 2007
Last Updated
11 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • male patients with LUTS associated with BPH diagnosed \> 3 months
  • IPSS score \> 13
  • voiding and storage symptoms
  • maximum flow rate of \> 4 mL/s and \< 15 mL/s

Exclusion Criteria

  • post void residual volume \> 200 mL
  • symptomatic urinary tract infection

Arms & Interventions

H

Intervention: tamsulosin hydrochloride

A

Intervention: Placebo

B

Intervention: solifenacin succinate

C

Intervention: solifenacin succinate

D

Intervention: solifenacin succinate

E

Intervention: tamsulosin hydrochloride

F

Intervention: tamsulosin hydrochloride

F

Intervention: solifenacin succinate

G

Intervention: tamsulosin hydrochloride

G

Intervention: solifenacin succinate

H

Intervention: solifenacin succinate

Outcomes

Primary Outcomes

Assess whether the combination of solifenacin succinate and tamsulosin hydrochloride provides improved efficacy compared to tamsulosin hydrochloride alone in males with LUTS associated with BPH

Time Frame: 12 weeks

Secondary Outcomes

  • Assess efficacy, safety, tolerability and PK of the combination of solifenacin succinate and tamsulosin hydrochloride(12 weeks)

Similar Trials